Table 1. The comparison of patient background between recurrence and non-recurrence.
| Variables | Recurrence (n=26) | Non-recurrence (n=64) | P value |
|---|---|---|---|
| Age (years) | 68 [62–71] | 68 [62–72] | 0.758 |
| SUVmax on FDG-PET | 5.70 [3.50–7.67] | 5.09 [3.32–7.04] | 0.408 |
| Serum CEA level | 4.00 [2.40–6.40] | 3.70 [2.18–7.70] | 0.841 |
| 2DS (mm) | 24.5 [18.3–29.8] | 21 [17.0–28.5] | 0.101 |
| Sex (male), n (%) | 14 (53.8) | 47 (73.4) | 0.085 |
| Smoking, n (%) | 0.124 | ||
| Non-smoker | 13 (50.0) | 19 (29.7) | |
| Ex-smoker | 10 (38.4) | 27 (58.6) | |
| Current smoker | 3 (11.5) | 18 (28.1) | |
| Procedure, n (%) | 0.270 | ||
| Lobectomy | 25 (96.2) | 55 (85.9) | |
| Segmentectomy/sublobar | 1 (0.8) | 9 (14.1) | |
| Pleural invasion, n (%) | 0.010 | ||
| + | 20 (76.9) | 29 (45.3) | |
| − | 6 (23.1) | 35 (54.7) | |
| Lymphatic invasion, n (%) | 0.167 | ||
| + | 9 (34.6) | 12 (18.8) | |
| − | 17 (65.4) | 52 (81.2) | |
| Vascular invasion, n (%) | 0.285 | ||
| + | 5 (19.2) | 6 (9.4) | |
| − | 21 (80.8) | 58 (90.6) | |
| EGFR, n (%) | 0.044 | ||
| Mutant | 12 (46.1) | 15 (23.4) | |
| WT | 14 (53.9) | 49 (76.6) |
Data are shown as median [IQR] or n (%). SUVmax, maximum standard uptake value; FDG PET, [18F] fluorodeoxyglucose positron emission tomography; CEA, carcinoembryonic antigen; 2DS, tumor diameter on two-dimensional axial CT; EGFR, epidermal growth factor receptor; WT, wild type; IQR, interquartile range; CT, computed tomography.